Ursodeoxycholic acid

Ursodeoxycholic acid accounts for a small part of human bile. After oral administration of ursodeoxycholic acid, the cholesterol saturation in bile is reduced by inhibiting the reabsorption of cholesterol in the intestine and reducing the secretion of cholesterol into bile. Cholesterol stones are gradually dissolved, probably due to the dispersion of cholesterol and the formation of liquid crystals. According to existing knowledge, the treatment of liver and cholestatic diseases with ursodeoxycholic acid capsules is mainly based on the relative replacement of lipophilic, detergent-like toxic bile acids by hydrophilic, cytoprotective and non-cytotoxic ursodeoxycholic acid, as well as the promotion of hepatocyte secretion and immunomodulation.

The main ingredient of this product is ursodeoxycholic acid. Its chemical name is 3a,7b-dihydroxy-5b-cholestane-24-acid.

Ursodeoxycholic acid is a white crystalline powder, odorless and bitter. It is almost insoluble in water, easily soluble in ethanol and glacial acetic acid, slightly soluble in imitation, and very slightly soluble in ether. This product is a white tablet.

This product is used for cholesterol gallstone formation and bile-deficient steatorrhea. It can also be used to prevent drug-induced stone formation and treat steatorrhea (after ileal resection).

Adult oral administration: 8-10 mg/kg daily, divided into two doses during the morning and evening meals. The shortest course of treatment is 6 months. If there is no improvement in ultrasound examination and cholecystography after 6 months, the drug can be discontinued; if the stones have partially dissolved, continue to take the drug until the stones are completely dissolved.

The toxicity and side effects of this product are less than those of chenodeoxycholic acid. It generally does not cause diarrhea. Other occasional adverse reactions include constipation, allergies, headaches, dizziness, pancreatitis, and tachycardia. During the treatment period, it may cause calcification of gallstones and soft stools.

Acute biliary infection, biliary obstruction, pregnant and lactating women.

Precautions during pregnancy and lactation: Pregnant and lactating women are prohibited from using.

Ursodeoxycholic acid capsules should not be taken at the same time as drugs such as cholestyramine (cholestyramine), colestipol (colestipol), aluminum hydroxide and/or aluminum hydroxide-magnesium trisilicate, because these drugs can bind to ursodeoxycholic acid in the intestine, thereby hindering absorption and affecting efficacy. If the above drugs must be taken, ursodeoxycholic acid capsules should be taken two hours before or two hours after taking the drug. Ursodeoxycholic acid capsules can increase the absorption of cyclosporine in the intestine. Patients taking cyclosporine should monitor the serum concentration of cyclosporine and adjust the dose of cyclosporine if necessary. In some cases, taking ursodeoxycholic acid capsules can reduce the absorption of ciprofloxacin.

Keep away from light and sealed

Panjin Hengchanglong Pharmaceutical Co., Ltd.

• Founded in:

  2002-01-09

• Address:

  Ping'an Township, Dawa County

• Tax NO.:

  91211100734207588A

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view